Clinical Trials Logo

Dyskinesias clinical trials

View clinical trials related to Dyskinesias.

Filter by:
  • Active, not recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06021756 Active, not recruiting - Parkinson's Disease Clinical Trials

Phase I Open-label Study of Low-dose Ketamine Infusion Treatment in Levodopa-Induced Dyskinesia in Parkinson's Disease

Start date: July 28, 2019
Phase: Phase 1
Study type: Interventional

The primary objective is to determine the tolerability and efficacy of a low-dose ketamine infusion for the treatment of Levodopa-Induced dyskinesias (LID), both acutely and during post-infusion evaluation (week 2-6), as measured by a change in patient diaries of dyskinesia and the UDysRS. Secondary objectives include observing the effects of ketamine on various symptoms of Parkinson's disease and Levodopa side effects. This includes the duration of "off," "on without dyskinesia," and "troublesome dyskinesia" time during waking hours, effects on chronic and acute pain, quality of life, and other general PD symptoms as noted in the Unified Parkinson's Disease Rating Scale. There is no highly effective treatment for levodopa-induced dyskinesia. This research study will use intermittent infusions of ketamine, on 10 volunteer subjects, which could provide significant improvement in dyskinesia utilizing a novel mechanism of action compared to current treatment strategies. Positive results in this study could lead to new novel treatments for dyskinesia and further development for other PD symptoms such as depression and pain.

NCT ID: NCT05714163 Active, not recruiting - Muscle Weakness Clinical Trials

Effects of Ai Chi on Scapular Muscle Activation in Overhead Athletes With Scapular Dyskinesis

Start date: October 16, 2022
Phase:
Study type: Observational

Scapular dyskinesis (SD) is common in overhead athletes and negatively influence the athletes' performance, increasing the risk of shoulder injury. The kinetic chain (KC) exercises for SD rehabilitation that emphasize importance of core strength and scapula stability during skillful performance. Ai Chi, the aquatic exercises performed in functional positions, which are adequate for power transfer of KC. This study will investigate the effect of KC-based water exercises, Ai Chi, on scapular muscles in overhead athletes with SD.

NCT ID: NCT04453995 Active, not recruiting - Parkinson Disease Clinical Trials

A Follow-up of the Influencing Factors of Dyskinesia in Patients With Parkinson's Disease

PDDIFFU
Start date: January 5, 2019
Phase:
Study type: Observational

Parkinson' patients who have not had dyskinesia would be observed for 2 years in a multicenter prospective study with the purposes to clarify the predicting factors of dyskinesia.

NCT ID: NCT04377945 Active, not recruiting - Parkinson Disease Clinical Trials

Study in Parkinson's Disease Patients With Dyskinesia With Combinations of JM-010 and Its Individual Components

SHINE
Start date: April 28, 2021
Phase: Phase 2
Study type: Interventional

This is a two-part, double-blind, placebo-controlled, randomized, multicenter Phase 2 clinical trial of JM-010 in patients with Parkinson's Disease.

NCT ID: NCT03956979 Active, not recruiting - Dyskinesias Clinical Trials

A Study in Parkinson's Disease in Patients With Moderate to Severe Dyskinesia

ASTORIA
Start date: July 22, 2019
Phase: Phase 2
Study type: Interventional

The current study will explore the efficacy, safety and tolerability of 2 dose combinations of JM-010 to determine the optimal doses of each component to be studied in confirmatory clinical trials.

NCT ID: NCT03801395 Active, not recruiting - Clinical trials for Primary Ciliary Dyskinesia

PCD New Gene Discovery

Start date: January 7, 2019
Phase:
Study type: Observational

This is a new gene discovery program for individuals with PCD who do not have a specific genetic etiology identified. Research procedures involve a single blood draw from the affected individual and from unaffected family members in an effort to identify new genetic targets.

NCT ID: NCT03704896 Active, not recruiting - Clinical trials for Primary Ciliary Dyskinesia

PRospective Observational Multicentre Study on VAriability of Lung Function in Stable PCD Patients

PROVALF-PCD
Start date: August 23, 2017
Phase:
Study type: Observational

Using routinely collected clinical data, this study aims to quantify intra-individual (i.e. in the same individual) variations between measurements of lung function in stable patients with primary ciliary dyskinesia (PCD), a rare genetic disease that causes lung damage.

NCT ID: NCT03319485 Active, not recruiting - Parkinson Disease Clinical Trials

ExAblate Pallidotomy for Medically-Refractory Dyskinesia Symptoms or Motor Fluctuations of Advanced Parkinson's Disease

Start date: February 9, 2018
Phase: N/A
Study type: Interventional

Evaluate the safety and efficacy of unilateral focused ultrasound pallidotomy using the ExAblate 4000 System in the management of dyskinesia symptoms or motor fluctuations for medication refractory, advanced idiopathic Parkinson's disease.

NCT ID: NCT03120650 Active, not recruiting - Ischemic Stroke Clinical Trials

Scalp Acupuncture for Dyskinesia After Ischemic Stroke

LUSA
Start date: January 20, 2017
Phase: N/A
Study type: Interventional

Scalp acupuncture formed by combining traditional Chinese acupuncture techniques and modern theories in medical anatomy has been widely used to treat ischemic stroke in China, but effective clinical trials that verify its efficacy are lacking. This study proposes to verify the effects of Lu's scalp acupuncture on ischemic stroke by comparing differential improvement of motor function between conventional rehabilitation alone and conventional rehabilitation with Lu's scalp acupuncture.

NCT ID: NCT02252380 Active, not recruiting - Parkinson's Disease Clinical Trials

ExAblate Transcranial MRgFUS for the Management of Treatment-Refractory Movement Disorders

Start date: May 2015
Phase: N/A
Study type: Interventional

The proposed study is to evaluate the effectiveness of ExAblate Transcranial MRgFUS as a tool for creating a unilateral lesion in the Vim thalamus or the globus pallidus (GPi) in patients with treatment-refractory symptoms of movement disorders.